Code |
Project Title |
Supervisor |
Institution |
mos23_16 |
mos23_16 PROTACS new computational methods, targets and experimental validation |
Ehmke Pohl |
Durham |
mos23_01 |
mos23_01 Synthetic antimicrobials based on natural toxins |
Tim Blower |
Durham |
mos23_02 |
mos23_02 Development of a new approach to targeted chelation therapies |
Will Brittain |
Durham |
mos23_03 |
mos23_03 DUNeS: Structure based development of dual specificity inhibitors of NLRP3 and SARM1 |
Agnieszka Bronowska |
Newcastle |
mos23_04 |
mos23_04 Development of DNA-PK-targeting PROTACs to maximise DNA-PK blockage in advanced prostate cancer |
Celine Cano |
Newcastle |
mos23_05 |
mos23_05 Identification of new molecular targets for NTDs |
Steven Cobb |
Durham |
mos23_06 |
mos23_06 Differential diagnostics for leishmaniasis - bench to field |
Paul Denny |
Durham |
mos23_07 |
mos23_07 Cell- and Tissue-targeted cyclic peptide discovery platform |
Akane Kawamura |
Newcastle |
mos23_08 |
mos23_08 Ribosomal glycopeptide production to investigate glycosylation changes in prostate cancer |
Tom McAllister |
Newcastle |
mos23_09 |
mos23_09 Structure guided approach to assay development for inhibiting Dengue virus replication |
Liz Morris |
Durham |
mos23_10 |
mos23_10 Mass spectrometry approaches to address capability gaps in drug discovery for membrane transporters |
Matthias Trost |
Newcastle |
mos23_11 |
mos23_11 Proteomics-based assessment of drug performance in vivo by establishing target engagement methods and characterizing new disease models |
Matthias Trost |
Newcastle |
mos23_12 |
mos23_12 Lead optimization by DNA-encoding |
Mike Waring |
Newcastle |
mos23_13 |
mos23_13 Expanding the Build-Couple-Transform Paradigm to develop highly diverse screening libraries for Drug Discovery
|
Mike Waring |
Newcastle |
mos23_14 |
mos23_14 CRISPR-mediated tagging of endogenous proteins for structural mapping of interactions |
Wyatt Yue |
Newcastle |
mos23_15 |
mos23_15 DNA Nanosensors for Metal Ion Cancer Biomarkers |
Harold Fellerman |
Newcastle |